A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects
Status:
Completed
Trial end date:
2018-12-07
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase 1/2 study. The study will evaluate the tolerability, safety and
activity of AMG 337 in Asian subjects who have advanced solid tumors (Phase 1) or subjects
with MET amplified tumors with a focus on gastric/gastroesophageal junction/esophageal
adenocarcinoma (Phase 2).